Informed Consent in the Genomics Era

Deborah Mascalzoni, Andrew Hicks, Peter Pramstaller, Matthias Wjst*

Summary Points

- Genetic cohort studies storing biological materials hold great promise for medical research, but also present new problems that are profoundly different from the classical clinical trial for which informed consent was developed.
- The classical risk/benefit analysis of physical harm doesn’t take into account new threats to the individual such as uninsurability, unemployability, genetic discrimination, or disruption of family relationships.
- Traditional informed consent may therefore no longer be appropriate when dealing with long-term studies using biological materials.
- Informed consent should be seen as an ongoing process between researcher and participant, and not just as a once-and-for-all decision.
- Research following the initial storage of samples needs to be likewise explained and may be announced using new communication methods.

Since the Nuremberg trials, informed consent (IC) has been recognized as a basic ethical requirement for research involving human participants [1] (Table 1). Such consent encompasses two distinct elements: (1) researchers communicate detailed information about study procedures, outcomes, risks, and benefits for the participating individual or community, and (2) after understanding and careful consideration, the participants consent to take part under these conditions. However, the suitability of IC for genomic studies has been recently challenged [2,3]. Because the research protocol for such studies may evolve over time, the condition in IC of providing detailed information for a well-defined protocol is not easily satisfied.

Large amounts of data stored as electronic records allow multiple post-hoc analyses, which in many cases were not foreseen at the beginning of a study. The potential for analysis is constantly growing and recently has increased dramatically with the development of high-throughput sequencing and genotyping technologies. More than one million genetic variants of an individual may be determined within hours—and even the full genetic sequence within weeks [3]. Such technical advances expose participants to a new class of risk different from the physical harm usually considered in ethical reviews [4,5]. Release of genetic information could lead to uninsurability, unemployability, discrimination, and the breakdown of family relationships by unintentionally demonstrating missing or unknown relatedness. Moreover, participants usually do not get any direct benefit from the research. All of these concerns raise the question: are IC procedures still in accordance with the currently accepted ethical standards of autonomy, beneficence, and non-maleficence?

There is pressure to harmonize different views, since a shared ethical and legal framework is still missing and approaches vary greatly [6–8]. A wide spectrum of opinions exists: Some researchers believe that available sample collections do not need any further consent, even for large-scale genotyping [9], while some institutional review boards recommend the destruction of samples immediately after testing (MW, personal observation).

Unfortunately, in current practice, the only moment when a person is really able to make a choice about participating in clinical research is when they sign the IC form. At this moment, the balance of power between overall research goals and individual interests should find equilibrium. As a study participant, however, one also has the right to know who owns the data, who guarantees proper handling, who will have further access to the data, and what security measures are in place. And all these concerns arise against a background in which the research questions themselves may rapidly change with the advancement of technical knowledge [10]. Any further genetic analysis may in fact severely compromise individual interests and autonomous choice, particularly if the individual is not fully aware of the very nature of the generated data and the implications of its use (or potential abuse). A stepwise informed consent should therefore be considered in accordance with the Council for International Organizations of Medical Sciences guidelines, one of the first to define IC not as a finite time step, but as an ongoing process [11] (Figure 1). Also, UNESCO’s International Declaration on Human Genetic Data states that “clear, balanced, adequate and appropriate information shall be provided to the person whose prior consent was developed.

The Essay section contains opinion pieces on topics of broad interest to a general medical audience.

Funding: The authors’ research is funded by the European Academy Bolzano. MW is further funded by Helmholtz Zentrum München grant number FE 75051 and the European Union project Europrevall. None of the authors received any specific funding to write this article, and no funding agency played a direct role in its preparation.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Mascalzoni D, Hicks A, Pramstaller P, Wjst M (2008) Informed consent in the genomics era. PLoS Med 5(9): e192. doi:10.1371/journal.pmed.0050192

Copyright: © 2008 Mascalzoni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: IC, informed consent

Deborah Mascalzoni, Andrew Hicks, Peter Pramstaller, and Matthias Wjst are at the Institute of Genetic Medicine, EURAC Research, Bozen, Italy. Matthias Wjst is also at the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

* To whom correspondence should be addressed.
E-mail: mwjst.de

Provenance: Not commissioned; externally peer reviewed
### Table 1. History: From an Early Informed Consent Proposal to Modern Recommendations for Genetic Studies

| Guidelines and Laws | Years | Source |
|---------------------|-------|--------|
| Nuremberg Code ([http://ohsr.od.nih.gov/guidelines/nuremberg.html](http://ohsr.od.nih.gov/guidelines/nuremberg.html)) | 1947 | A first generally accepted code of ethics in medical research |
| Declaration of Helsinki ([http://www.wma.net/e/policy/b3.htm](http://www.wma.net/e/policy/b3.htm)) | 1964, 1975, 1983, 1989, 2000, 2002, 2004; next amendment October 2008 | Guidelines by the World Medical Association |
| Belmont Report ([http://ohsr.od.nih.gov/guidelines/belmont.html](http://ohsr.od.nih.gov/guidelines/belmont.html)) | 1973 | US government regulations |
| International Ethical Guidelines for Biomedical Research ([http://www.cioms.ch/frame_guidelines_nov_2002.htm](http://www.cioms.ch/frame_guidelines_nov_2002.htm)) | 1982, 1993, 2002 | World Health Organization and Council for International Organizations of Medical Sciences |
| Statement on the Principled Conduct of Genetics Research ([http://www.eubios.info/HUGO.htm](http://www.eubios.info/HUGO.htm)) | 1996 | Human Genome Organisation Ethical, Legal and Social Issues Committee |
| Convention on Human Rights and Biomedicine ([http://conventions.coe.int/Treaty/Commun/QueVoulezVous.asp?NT=164&CL=ENG](http://conventions.coe.int/Treaty/Commun/QueVoulezVous.asp?NT=164&CL=ENG)) | 1997 | Council of Europe |
| Universal Declaration on the Human Genome and Human Rights ([http://portal.unesco.org/sh/en/ev.php-URL_ID=1881&URL_DO=DO_TOPIC&URL_SECTION=201.html](http://portal.unesco.org/sh/en/ev.php-URL_ID=1881&URL_DO=DO_TOPIC&URL_SECTION=201.html)) | 1997 | UNESCO’s 29th General Conference |
| Genomics and World Health ([http://whqlibdoc.who.int/hq/2002/a74580.pdf](http://whqlibdoc.who.int/hq/2002/a74580.pdf)) | 2002 | World Health Organization |
| International Declaration on Human Genetic Data ([12]) | 2003 | UNESCO |
| Pharmacogenetics: Ethical Issues ([http://www.nuffieldbioethics.org/go/ourwork/pharmacogenetics/publication_314.html](http://www.nuffieldbioethics.org/go/ourwork/pharmacogenetics/publication_314.html)) | 2003 | Nuffield Council of Bioethics |
| Human Tissue Act ([http://www.opsi.gov.uk/acts/acts2004/ukpga_20040030_en_1](http://www.opsi.gov.uk/acts/acts2004/ukpga_20040030_en_1)) | 2004 | UK framework for use of organs and tissue |
| Ethical, Legal and Social Aspects of Genetic Testing: Research, Development and Clinical Applications ([http://ec.europa.eu/research/conferences/2004/genetic/pdf/report_en.pdf](http://ec.europa.eu/research/conferences/2004/genetic/pdf/report_en.pdf)) | 2004 | Report for the European commission |
| Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Preservation, Storage and Distribution of Human Tissues and Cells ([http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:038:0040:01:EN:HTML](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:038:0040:01:EN:HTML)) | 2004 | European parliament and of the council (directive 2004/23/EC) |
| Biobanken für die Forschung ([Research Biobanks] ([http://www.ethikrat.org/de_publikationen_ner/stellungnahmen.php](http://www.ethikrat.org/de_publikationen_ner/stellungnahmen.php)) | 2004 | Deutscher Ethikrat |
| 25 Recommendations on the Ethical, Legal and Social Implications of Genetic Testing ([http://ec.europa.eu/research/conferences/2004/genetic/recommendations_en.htm](http://ec.europa.eu/research/conferences/2004/genetic/recommendations_en.htm)) | 2004 | European Commission |
| Universal Declaration on Bioethics and Human Rights ([http://portal.unesco.org/sh/en/ev.php-URL_ID=1883&URL_DO=DO_TOPIC&URL_SECTION=201.html](http://portal.unesco.org/sh/en/ev.php-URL_ID=1883&URL_DO=DO_TOPIC&URL_SECTION=201.html)) | 2005 | World Health Organization |
| DRAFT International Ethical Guidelines for Epidemiological Studies ([http://www.cioms.ch/080221feb_2008.pdf](http://www.cioms.ch/080221feb_2008.pdf)) | 2008 | World Health Organization and Council for International Organizations of Medical Sciences |
| Genetic Information Nondiscrimination Act ([http://www.oecd.org/document/12/0,3343,en_2649_34537_4030292_1_1_1_1,00.html](http://www.oecd.org/document/12/0,3343,en_2649_34537_4030292_1_1_1_1,00.html)) | 2008 | United States of America |
| DRAFT Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Genetic Testing for Health Purposes ([http://assembly.coe.int/Main.asp?link=/Documents/WorkingDocs/Doc07/EDOC11466.htm](http://assembly.coe.int/Main.asp?link=/Documents/WorkingDocs/Doc07/EDOC11466.htm)) | 2008 | Council of Europe |
| Guidelines for Human Biobanks and Genetic Research Databases ([http://www.oecd.org/document/12/0,3343,en_2649_34537_4030292_1_1_1_1,00.html](http://www.oecd.org/document/12/0,3343,en_2649_34537_4030292_1_1_1_1,00.html)) | 2008 (under public scrutiny) | Organisation for Economic Co-operation and Development |

Adapted from [25].
doi:10.1371/journal.pmed.0050192.t001

free, informed and express consent is sought” [12]. This goal seems to be largely in contrast with procedures in current genomic studies. Since this kind of detailed information is difficult to provide, a frequently favored approach is to ask for a broad consent [13].

But a more detailed analysis of the rationale behind broad consent shows that “broad consent” is seldom if ever justified [14]. Although proponents of “broad consent” argue that individuals will maintain a right to withdraw from the study, this right seems to be more of a fig leaf than a true option. As the value of stored samples increases over time due to additional data being generated, a later withdrawal of consent is difficult; it would require not only removal of printed lists and questionnaires but also deletion of current computer files including backups as well as all samples and aliquots. Therefore the Council for International Organizations of Medical Sciences guidelines recommend broad consent be sought only under certain circumstances [11]. Such circumstances include (1) obtaining the approval of an ethical committee and (2) keeping data and samples anonymous. Anonymity, however, is in practice impossible to guarantee [15,16]. Genetic data are intrinsically self-identifying, hence their use in criminal forensic investigations [17]. Advances in computer science allow cross-matching...
of data not previously foreseen, as shown in the “Netflix” affair (http://www.nytimes.com/2007/06/04/technology/04netflix.htm). With every bit of additional data, anonymity is decreasing, in particular when genetic testing may be used to reconstruct ethnicity, sex, age, height, and other body characteristics such as eye and hair color [18]. Unfortunately, nobody can foresee the implications of these threats to genetic privacy. With the stability of DNA and its potential for use even with only trace amounts, genomics studies will have an almost infinite duration if not actively terminated. Moreover, any genetic variant determined in someone’s DNA will have a good chance of also being present in that person’s children (who may have never consented to the analysis of their genome in the first place). Hence there is a community dimension to IC for genomic studies, especially when combined with genealogical data.

There is substantial uncertainty in the development of genomics projects that may arise, which cannot be foreseen even by institutional review boards. Moreover, many researchers in the field currently see their institutional review board only as an “obstacle course” with an uncertain outcome [19]. With many issues now arising in the interplay between research-driven interests, new discoveries, and society, such as allocation of research resources, data ownership, and publication of results, the problem is not so much the doctrine of IC but its implementation [20]. Most if not all of the problems could certainly be addressed by a better researcher–participant relationship [21]. As Veatch notes: “In the past, research subjects have all too often been treated as passive “material” suitable for providing additional data points…[while] partners normally come together not because they share exactly the same interests or abilities, but because there is some mutuality of interests, some common point of intersection where each can help the other” [21]. A research partnership will demonstrate not only the potential benefits of such research, but also the current difficulties that need to be addressed. Reassuring research participants that anonymity will be preserved just to avoid a deeper discussion about the issues involved in genomics research may undermine the trust and collaborative spirit that is needed between science and society.

In current genomic studies, the relationship between researcher and participant may be different from the traditional physician–patient studies. Most of the research staff in current genomics projects will not have any direct contact with participants. In addition, these studies are usually not expected to give any direct benefit to the participants, as they are not seeking any new treatment. These two features of genomics research need to be reflected in the partnership between all actors involved in the research. Where possible, participants should be actively involved in information exchange and the decision-making process [3,18]. Several authors have already suggested an exploratory or participatory process prior to the implementation of a research project that should provide a better understanding of relevant issues through interest groups, consensus conferences, meetings, or surveys [10,16,20]. We propose a circular process of information exchange (Figure 1). Following a first phase of general information, a more detailed information exchange then takes place. IC in this context should be defined as an ongoing process instead of a once-and-for-all-time decision [22]. Understanding IC as

---

**Box 1: An Implementation Plan**

- Carefully inform the community about the planned study
- Collect feedback and take it into account for policy changes
- Redesign informed consent forms so that consent may be initially given only for interview, physical examination, data, and sample storage
- Explain terms without ambiguity (for instance, explain that anonymity may be limited even with anonymized samples)
- Explain opt-in/opt-out procedures for further genetic testing
- Establish conventional communication channels (face-to-face or group meetings, letters) but also use electronic communications (e-mail alerts, Web sites, RSS feeds, electronic voting, blogs, chat rooms, social platforms)
- Offer freephone number, SMS broadcasts
- Develop transparent annotation rules for individual genetic data
- Respect the right to know and the right not to know
- Adjust protocols to local needs and individual wishes

---

**Figure 1. Informed Consent as a Process**

doi:10.1371/journal.pmed.0050192.g001
Researchers and participants as partners in an open dialogue is a great opportunity to build trust between science and society, while giving new force and meaning to the ethics of research. ■

Supporting Information

Alternative Language Text S1.
Italian translation of the summary points by D. Mascalzoni
Found at doi:10.1371/journal.pmed.0050192.sd001 (24 KB DOC).

Alternative Language Text S2.
German translation of the summary points by S. Geiser
Found at doi:10.1371/journal.pmed.0050192.sd002 (25 KB DOC).

Acknowledgments

MW wishes to thank Elisabeth André for many helpful discussions and Rasso Ranzinger for help with the literature. DM wishes to thank Scott Melville for constructive comments during the revision process.

References

1. Taylor T (1995) The anatomy of the Nuremberg Trials. London: Bloomsbury Publishing. 703 p.
2. Knoppers B (2005) Consent revisited: Points to consider. Health Law Rev 15: 33-38.
3. Petersen A (2007) Biobanks “engagements”: Engendering trust or engineering consent? Genomics Soc Policy 3: 31-43.
4. Funtowicz SR (1993) Science for the post-normal age. Futures 25: 735-755.
5. Krinsky S (2004) Science in the private interest. Has the lure of profits corrupted biomedical research? Lanham (MD): Rowman & Littlefield. 272 p.
6. Knoppers B (2005) Biobanking: International norms. J Law Med Ethics 33: 7-14.
7. Knoppers B (2004) Biobanks: Simplifying consent. Nat Rev Genet 5: 485.
8. Gibbons S, Helgason H, Kaye J, Normper A, Wendel I. (2005) Lessons from European population genetic databases: Comparing the law in Iceland, Estonia, Sweden and the United Kingdom. Eur J Health Law 12: 103-133.
9. Wichmann H, Gieger C, Illig T (2005) KORA-gen—Resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67 (Suppl 1): S26-S30.
10. Edwards J (2002) Taking public understanding seriously. New Genet Soc 21: 315-325.
11. Medical Research Council, Wellcome Trust (2006) CIOMS guidelines “Special ethical considerations for epidemiological research”: Response from the Medical Research Council and the Wellcome Trust. Available: http://www.wellcome.ac.uk/stellent/groups/corporate/site/@policy_communications/documents/web_document/WTX035295.pdf. Accessed 13 August 2008.
12. United Nations Educational, Scientific and Cultural Organization (2003) International declaration on human genetic data. Available: http://portal.unesco.org/shs/en/c/ev.php-URL_ID=1882&URL_DO=DO_TOPIC&URL_SECTION=201.html. Accessed 13 August 2008.
13. Winickoff D (2000) The biobanks law and decode genetics: Rhetoric equals cash in Iceland. GeneWatch 13: 4-6.
14. Caulfield T (2007) Biobanks and blanket consent: The proper place of the public good and public perception rationales. Kings Coll Law J 18: 209-226.
15. Arnason V (2004) Coding and consent: Moral challenges of the database project in Iceland. Bioethics 18:1: 27-49.
16. Tutton R (2004) Genetic databases: Socio-ethical issues in the collection and use of DNA. London: Routledge. 208 p.
17. Liu Z, Altman RB, Owen AB (2006) Confidentiality in genome research. Science 315: 441-442.
18. Lunshof JE, Chadwick R, Vorhaus DB, Church GM (2008) From genetic privacy to open consent. Nat Genet 9: 406-411.
19. Ledford H (2007) Human-subjects research: Trial and error. Nature 448: 539-532.
20. Lutz CW, Appelbaum PS (1998) Two models of implementing informed consent. Arch Intern Med 148: 1385-1389.
21. Veatch RM (1987) The patient as partner. A theory of human-experimentation ethics. Indiana University Press. 276 p.
22. Weill C (2003) Can consultation of both, experts and the public help developing public policy? Sci Public Policy 30: 199-205.
23. Kohane IS, Mandell KD, Taylor PL, Holm IA, Nigrin DJ, et al. (2007) Reestablishing the researcher-patient compact. Science 316: 836-837.
24. Caulfield T, McGuire AL, Cho M, Buchanan JA, Burgess MM, et al. (2008) Research ethics recommendations for whole-genome research: Consensus statement. PLoS Biol 6: e73. doi:10.1371/journal.pbio.0060073
25. Arnold K, van der Walt J (2007) Ethical issues in human genetic research: The global experience. In: Weiner MP, Gabrielson SR, Stephens JC, editors. Genetic variation. A laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbour Laboratory Press. 472 p.